Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 6th. Analysts expect Praxis Precision Medicines to post earnings of ($2.01) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.38) by $0.64. Praxis Precision Medicines had a negative return on equity of 61.47% and a negative net margin of 6,987.01%. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $1.44 million. On average, analysts expect Praxis Precision Medicines to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.
Praxis Precision Medicines Stock Up 2.4 %
Shares of PRAX traded up $1.68 during trading hours on Tuesday, reaching $71.70. The company’s stock had a trading volume of 64,734 shares, compared to its average volume of 272,698. The company has a 50 day moving average of $62.94 and a two-hundred day moving average of $53.41. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -6.77 and a beta of 2.67. Praxis Precision Medicines has a 1-year low of $13.01 and a 1-year high of $75.73.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Praxis Precision Medicines
Praxis Precision Medicines Company Profile
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Recommended Stories
- Five stocks we like better than Praxis Precision Medicines
- Canada Bond Market Holiday: How to Invest and Trade
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Insider Buying Signals Upside for These 3 Stocks
- Investing In Preferred Stock vs. Common Stock
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.